Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine.
Martine Hoogendoorn,Isaac Corro Ramos,Michael Baldwin,Nuria González-Rojas Guix,Maureen P.M.H. Rutten-van Mölken +4 more
Reads0
Chats0
TLDR
A unique patient-level simulation model is developed that can be used to evaluate COPD treatment options for a variety of subgroups and results for a selection of treatment scenarios and subgroups were shown to demonstrate the potential of the model.About:
This article is published in Value in Health.The article was published on 2019-03-01 and is currently open access. It has received 16 citations till now. The article focuses on the topics: Quality-adjusted life year & Cost effectiveness.read more
Citations
More filters
Journal ArticleDOI
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
TL;DR: Despite substantial progress in reducing the global impact of many non-communicable diseases, including heart disease and cancer, morbidity and mortality due to chronic respiratory disease continues to increase despite the identification of cigarette smoking as the major risk factor for the disease more than 50 years ago as discussed by the authors .
Journal ArticleDOI
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Daiana Stolz,Takudzwa Mkorombindo,Desiree M. Schumann,Alvar Agusti,Samuel Y. Ash,Mona Bafadhel,Chun-Ai Bai,James D. Chalmers,Gerard J. Criner,Shyamali C. Dharmage,Frits M.E. Franssen,Urs Frey,MeiLan K. Han,Nadia N. Hansel,Nathaniel M. Hawkins,Ravi Kalhan,Melanie Konigshoff,Fanny W.S. Ko,Trisha M. Parekh,Pippa Powell,Maureen P.M.H. Rutten-van Mölken,Jodie L. Simpson,Don D. Sin,Yuanlin Song,Béla Suki,Thierry Troosters,George R. Washko,Tobias Welte,Mark T. Dransfield +28 more
TL;DR: This work advocates for broader understanding of risk factors and the preventive measures necessary to avoid future cases of COPD, disruptive approaches to diagnosis that are not solely based on spirometric airflow limitation but also involve identification of early pathological changes that are more amenable to reversal, and a new approach to the diagnosis and assessment of exacerbations of COPd that focuses on disease mechanisms.
Journal ArticleDOI
Personalized medicine for patients with COPD: where are we?
Frits M.E. Franssen,Peter Alter,Nadav Bar,Birke J. Benedikter,Stella Iurato,Dieter Maier,Michael Maxheim,Fabienne K. Roessler,Martijn A. Spruit,Martijn A. Spruit,Claus Vogelmeier,Emiel F.M. Wouters,Bernd Schmeck +12 more
TL;DR: The current status and unmet needs regarding personalized medicine for patients with COPD are described, and a systems medicine approach is proposed, integrating genetic, environmental, (micro)biological, and clinical factors in experimental and computational models in order to decipher the multilevel complexity of COPD.
Journal ArticleDOI
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.
Deborah A. Marshall,Luiza R Grazziotin,Dean A. Regier,Sarah Wordsworth,James M. Buchanan,James M. Buchanan,Kathryn A. Phillips,Maarten Joost IJzerman +7 more
TL;DR: Simulation models are well suited for economic evaluation in PM because they enable patient-level analyses and can capture the dynamics of interventions in complex systems specific to the context of healthcare service delivery.
Journal Article
A UK based cost-utility analysis of indacaterol - A once-daily maintenance bronchodilator for patients with COPD
TL;DR: In assessing the cost-effectiveness of COPD therapies, this study has the advantage of using real world evidence on the resource use associated with COPD management across the spectrum of the disease, and demonstrates that indacaterol dominates both tiotropium and salmeterol in the base case and is likely to remain cost-effective under a range of assumptions.
References
More filters
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Journal ArticleDOI
A 4-Year Trial of Tiotropium in chronic obstructive pulmonary disease
Donald P. Tashkin,Bartolome R. Celli,Stephen Senn,D Burkhart,Steven Kesten,Shailendra Menjoge,Marc Decramer +6 more
TL;DR: Therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1).
Unit Costs of Health and Social Care 2014
TL;DR: The 2014 edition of the PSSRU Unit-Costs series as mentioned in this paper is the latest volume in a well-established series bringing together information from a variety of sources to estimate national unit costs for a wide range of health and social care services.
Journal ArticleDOI
Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update
TL;DR: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) programme was initiated in January 1997 to increase awareness of chronic obstructive pulmonary disease (COPD) and to decrease morbidity and mortality from this chronic lung disorder.